Semaglutide Stability Guide: What the 56-Day Label Supports

Semaglutide is a GLP-1 receptor agonist with strong label-backed stability data for approved pen formulations, but much weaker direct evidence for reconstituted research vials.

This guide separates those two contexts instead of treating them as interchangeable.

Start with the strongest source, then stop where the source stops

For pharmaceutical semaglutide, the official label is the strongest source in the repo. According to the Ozempic FDA label and its DailyMed counterpart, the product is refrigerated before first use and can then be stored for 56 days either at room temperature up to 30°C or in the refrigerator after first use.

That is the right place to begin, but it is also the right place to draw a line. The manufacturer supports a 56-day in-use window for the labeled pen formulation. That is a strong fact about Ozempic or Wegovy handling. It is not automatic proof for every reconstituted semaglutide vial outside that formulation context.

Why the vial discussion is not the same as the pen discussion

The obvious rebuttal is “but I have a vial, not a pen,” and that is exactly the distinction that matters. The commercial pen includes a specific buffer system, specific preservatives, and validated manufacturing controls designed around that formulation. Most research workflows do not reproduce that setup. They begin with a lyophilized powder and a solvent such as BAC water, which introduces a different handling path and a different evidence boundary.

So even when the active molecule is still semaglutide, the formulation story has changed. The pen label supports the product it was written for. It does not directly validate the stability window of a reconstituted research vial.

What the conservative storage view looks like in practice

For reconstituted semaglutide, refrigeration remains the safest routine default because cooler storage reduces degradation pressure even when room-temperature resilience exists in the approved pen formulation. A short accidental room-temperature exposure is not automatically catastrophic, but it should not be used as proof that all research-vial potency is unaffected either. The honest position is that the event is lower-risk than many people fear, yet still not directly label-backed for the reconstituted vial context.

Freezing stays in a different category. The label explicitly says not to freeze, and the broader solution-phase chemistry concern is that freezing can promote aggregation and structural stress. That is one of the cases where the most conservative handling rule still makes sense even when the exact research-vial penalty is not directly measured for every setup.

What the 56-day label does not authorize

For research purposes, the 56-day Ozempic label should not be presented as automatic proof that every punctured reconstituted semaglutide vial is validated for 56 days. If a longer semaglutide storage window appears in a research-facing workflow, it should be described as a conservative PeptideClock model estimate or extrapolation rather than as a direct FDA-backed claim for reconstituted-vial use.

Visual Inspection Checklist

Before every use, check your vial. Semaglutide solution should be:

• ✅ Colorless
• ✅ Clear
• ✅ Free of particles

Discard if: It looks cloudy, has white strings floating in it, or has changed color.

Summary

Semaglutide has unusually strong stability support in approved formulations compared with many peptides discussed in research settings. But that strength should not be overstretched. Keep the vial cold, do not freeze it, treat longer research-vial windows conservatively, and keep the evidence tier visible whenever the discussion moves away from the labeled pen and toward a reconstituted research workflow.

---

---

References & Evidence

1. Ozempic® (semaglutide) Prescribing Information. FDA label (2025). Full label PDF | DailyMed structured label — Source for 56-day in-use stability window, “Do Not Freeze” instruction, storage temperature (2–8°C before use; up to 30°C or 2–8°C after first use).

2. Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021 Feb 18;384(11):989-1002. PMID 33567185 — STEP-1 trial: −14.9% mean body weight loss vs −2.4% placebo (68 weeks).

3. de Vries F, et al. “Semaglutide preformulation stability pathways (deamidation, hydrolysis, fibrillation).” J Pept Sci. 2025. DOI 10.1002/psc.70039 — Molecular stability characterization of semaglutide in solution.

4. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. EMA — Framework for stability window assignment.

Important Distinction: The 56-day stability data applies to Ozempic/Wegovy pens containing proprietary formulation controls. Reconstituted research-grade semaglutide in BAC water does not have an equivalent FDA-validated stability assay. Any longer research-vial window should therefore be presented as a conservative extrapolation or model estimate, not as a direct label claim.